|
August 15, 2010
Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis ...
JAIDS Journal of Acquired Immune Deficiency Syndromes: "Conclusions: Maraviroc-containing antiretroviral regimens maintained durable responses in treatment-experienced patients with R5 HIV-1 through 96 weeks of treatment with a safety profile similar to placebo."
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment